The ab-normal elevation of Bcl-2 in FLT3-ITD-positive blasts protects tumor cells from apoptosis, and the Bcl-2 protein level is not decreased when FLT3 inhibitors attenuate the phosphorylation of FLT3 (86–88). The gene discussed is BCL2; the disease is neoplasm.